Institut Jules Bordet in Brussels has reached a significant milestone in radiation oncology, becoming one of only three institutions globally to fully integrate Elekta Evo with CBCT-based online adaptation using Elekta ONE | Online into its clinical workflow. This isn’t simply about adopting new technology; it represents a crucial step towards increasingly personalized and precise cancer treatment, minimizing side effects and maximizing efficacy.
- Precision Radiation Therapy Advances: The implementation of Elekta Evo and Elekta ONE | Online signifies a move towards adaptive radiotherapy, allowing for real-time adjustments based on individual patient anatomy and tumor response.
- Global Leadership: Institut Jules Bordet joins an elite group of institutions pioneering this advanced technology, solidifying its position as a leader in radiation oncology innovation.
- Teamwork & Investment: The success highlights the critical role of multidisciplinary collaboration and institutional investment in driving advancements in patient care.
The increasing sophistication of radiation therapy is driven by a growing understanding of the complexities of cancer and the limitations of traditional treatment approaches. Historically, radiation plans were based on initial imaging, but tumors can shrink or change shape during treatment, and patients can move slightly during delivery. CBCT (Cone Beam Computed Tomography) allows for daily imaging, and Elekta ONE | Online automates the adaptation of the treatment plan to these changes. This minimizes radiation exposure to healthy tissue and ensures the tumor receives the optimal dose. The trend towards adaptive radiotherapy is accelerating as technology improves and the demand for personalized cancer care increases.
This achievement at Institut Jules Bordet is a testament to the dedication of its medical physics, radiation oncology, and RTT teams, as well as the support from Elekta. The collaborative effort, led by Younes Jourani and key individuals like Zelda Paquier and Nicolas Jullian, underscores the importance of interdisciplinary teamwork in successfully implementing complex technologies.
The Forward Look: We can anticipate several key developments stemming from this implementation. First, expect a surge in data collection and analysis focused on patient outcomes with this new technology. Institut Jules Bordet will likely publish its findings, contributing to the growing body of evidence supporting adaptive radiotherapy. Second, other leading cancer centers will be watching closely, and we can expect increased adoption of similar systems globally. The challenge will be ensuring equitable access to these advanced technologies. Finally, further integration of artificial intelligence (AI) into the workflow is likely, potentially automating even more aspects of treatment planning and adaptation, leading to even greater precision and efficiency. The focus will shift from simply *implementing* the technology to *optimizing* its use and expanding its application to a wider range of cancer types.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
